ABSTRACT
approximately 115 million people globally (1.6% of the world's population) [1] . Eleven million of these individuals are below 15 years of age, of whom 5 million are viremic [1] . Children in China, Pakistan, Nigeria, Egypt, India and Russia account for more than 50% of the total pediatric infections [1] . Pediatric HCV infection prevalence varies significantly by region, ranging from 0.05-0.36% in the United States and Europe to 1.8-5.8% in some developing countries [2] . A similar trend is observed in the ratio of the prevalence of HCV in children compared to adults, which varies from approximately 1:25 in high-income countries to 1:4 in middle-income countries, and as high as 1:2 in low-income countries [1] . While vertical (motherto-infant) transmission is the major route of pediatric infection in developed countries, horizontal transmission (e.g. contaminated needles or blood transfusion products) is the major route in developing countries [2] . Copyright © ESPGHAN and NASPGHAN. All rights reserved.
Eleven of these 28 patients (39%) ultimately achieved SVR, which was maintained in all patients 2 years after completing treatment.
Longer-term durability of response in children treated with PegIFN with or without RBV has not been reported to date. In adults, durability of SVR 5 years after completing PegIFN treatment has been observed to be >99% [4] and cirrhosis appears to be a risk factor for long-term relapse [5] .
The only published report of long-term follow-up in children is following non-pegylated interferon treatment thrice weekly with RBV, where the Kaplan-Meier estimate for sustained response at 5 years was 98% (95% CI, 95-100%) [6] .
In adults with genotype 1 infection, several independent genome-wide association studies (GWASs) reported single nucleotide polymorphisms (SNP's) near the IL28B (IFN-k) locus to be predictive of treatment response [7, 8] . Although recently a few pediatric studies have explored the effect of IL28B polymorphism on SVR in children, its role as a predictor of durability of response to treatment is still undetermined [9] .
The purpose of this study was to perform a long-term follow-up (LTFU), up to 7 years after cessation of therapy, of a group of children previously treated with PegIFN alfa-2a ± RBV in the PEDS-C study, and assess the long-term durability of SVR, long-term safety and tolerability, and the association between IL28B polymorphism and treatment response.
METHODOLOGY Study Population
Patients were eligible for inclusion if they completed treatment with PegIFN alfa-2a ± RBV in the PEDS-C study. Patients were excluded if they received PegIFN alfa-2a ± RBV after the initial study period, received other treatment that the investigator judged could affect growth
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Statistical Analyses
Descriptive statistics were used for all analyses with exploratory analyses performed as appropriate. All statistical tests were two-sided and used the conventional p<0.05 level of significance, with χ 2 and independent t-test being used as appropriate. RNA values were logtransformed to improve interpretability. All analyses were performed using SAS software version 9.2.
RESULTS

Subject Characteristics
All 93 patients who had completed the 2-year follow up in the original PEDS-C study, from 8 participating sites, were considered for enrollment. Thirty-eight were available and willing to participate in the LTFU study. Of the 55 others: 26 were not contactable, 8 had moved from the area, 7 received PegIFN/RBV re-treatment and 14 either refused consent or could not participate for other reasons. The patient disposition in the original PEDS-C study and this LTFU study is shown in Figure 1 .
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The LTFU cohort was found to be representative of the original PEDS-C cohort, both in terms of baseline characteristics (e.g. HCV genotypes) and treatment received (see Table) . Twenty-one 
IL28B and SVR
IL28B CC genotype was associated with higher rate of SVR, compared to CT/TT genotype (67% vs. 30% respectively, p = 0.028) (Figure 2 ).
Safety Analyses
There were no patient deaths and only 1 serious adverse event (hospitalization for depression) was reported. This SAE occurred 6.5 years post-treatment and was deemed unrelated to study treatment. There were no clinically significant changes in any laboratory or vital sign parameters with the exception of the HCV RNA and ALT values discussed above.
Long-term growth outcomes have been previously reported [11] , and overall no long-term effects on height were observed. The results of health-related quality of life questionnaires will be reported separately.
DISCUSSION
The major finding of this study is that SVR following PegIFN alfa-2a ± RBV therapy in children with CHC is durable in 100% of patients for 4.4 to 7.7 years after treatment cessation. IL28B CC genotype was also observed to be associated with a greater chance of an SVR (p=0.028), which is consistent with data from adult and recent pediatric studies with CHC. Furthermore, PegIFN alfa-2a also shows an excellent long-term safety profile in treatment of children with HCV, including absence of long-term effects on growth [11] .
The significance of the above finding is that PegIFN alfa-2a is currently widely available to the considerable global population of children and adolescents with HCV. Indeed, it has been estimated that approximately 50,000 HCV-infected infants are born every year [12] , a fact which is especially sobering given that at present there is no known way to prevent maternal-fetal transmission.
Although direct acting anti-viral agents currently hold great promise for highly effective interferon-free treatment regimens [13] , none have yet been approved for use in children and there could be challenges to widespread availability to children, particularly in low-income countries where the prevalence and burden of HCV infection is greatest.
The main limitation of this study is the relatively small number of patients that participated in the long-term follow-up. This is not surprising given that the average age of enrollees in the original PEDS-C study was 11 years and the long-term follow-up lasted up to 7.7 years after cessation of therapy. This meant that many patients had moved away from home for higher education or employment and were simply not available for participation in the LTFU study. However, the fact that the baseline and treatment characteristics of the LTFU cohort did not differ from the PEDS-C cohort indicates that the smaller LTFU cohort is representative of the original larger
cohort. Given that the LTFU cohort is representative of the larger cohort, it is unlikely that the 100% long-term durability rates observed in the LTFU cohort would significantly differ if the entire PEDS-C cohort participated in the LTFU.
Overall, the PEDS-C LTFU data indicate that children who achieve SVR during treatment with PegIFN alfa-2a, with or without RBV, have a very high likelihood of long-term maintenance of that response. Given the ~5 million HCV-infected children in the world, the current lack of approved direct-acting antiviral interferon-free regimes in the pediatric population, as well as the potential limited access to interferon-free regimens in the developing countries where HCV prevalence is highest, it is reassuring to confirm that SVR achieved in children with CHC with the current standard of care will be maintained for many years. 
